3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Gastrointestinal Stromal Tumors
17
Sarcoma
6
Sarcoma, Ewing
5
Osteosarcoma
5
Neoplasm Metastasis
4
Rhabdomyosarcoma
3
Colorectal Neoplasms
3
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Chondrosarcoma
2
Bone Neoplasms
2
Wilms Tumor
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Patient Compliance
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Interventions
regorafenib
1
amino-acid, glucose, and electrolyte solution
1
PM 01183
1
Irinotecan
1
E-7386
1
Clinical Trials, Phase II as Topic
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
regorafenib
×
Sarcoma
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled